GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medlab Clinical Ltd (ASX:MDC) » Definitions » EV-to-FCF

Medlab Clinical (ASX:MDC) EV-to-FCF : -3.67 (As of Sep. 22, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Medlab Clinical EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Medlab Clinical's Enterprise Value is A$11.00 Mil. Medlab Clinical's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was A$-3.00 Mil. Therefore, Medlab Clinical's EV-to-FCF for today is -3.67.

The historical rank and industry rank for Medlab Clinical's EV-to-FCF or its related term are showing as below:

ASX:MDC' s EV-to-FCF Range Over the Past 10 Years
Min: -45.22   Med: -4.08   Max: 0.46
Current: -3.67

During the past 8 years, the highest EV-to-FCF of Medlab Clinical was 0.46. The lowest was -45.22. And the median was -4.08.

ASX:MDC's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 8.225 vs ASX:MDC: -3.67

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-09-22), Medlab Clinical's stock price is A$6.60. Medlab Clinical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-1.714. Therefore, Medlab Clinical's PE Ratio for today is At Loss.


Medlab Clinical EV-to-FCF Historical Data

The historical data trend for Medlab Clinical's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medlab Clinical EV-to-FCF Chart

Medlab Clinical Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-FCF
Get a 7-Day Free Trial -5.95 -3.14 -3.61 -1.29 -2.71

Medlab Clinical Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -1.29 - -2.71 -

Competitive Comparison of Medlab Clinical's EV-to-FCF

For the Biotechnology subindustry, Medlab Clinical's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medlab Clinical's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medlab Clinical's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Medlab Clinical's EV-to-FCF falls into.



Medlab Clinical EV-to-FCF Calculation

Medlab Clinical's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=11.003/-3.001
=-3.67

Medlab Clinical's current Enterprise Value is A$11.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medlab Clinical's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was A$-3.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medlab Clinical  (ASX:MDC) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Medlab Clinical's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=6.60/-1.714
=At Loss

Medlab Clinical's share price for today is A$6.60.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Medlab Clinical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-1.714.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Medlab Clinical EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Medlab Clinical's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Medlab Clinical Business Description

Traded in Other Exchanges
N/A
Address
11 Lord Street, Unit 5, Botany, NSW, AUS, 2019
Medlab Clinical Ltd is a medical research and development company. It is engaged in researching and formulating novel biotherapeutics to improve health outcomes in early to moderate stage chronic diseases such as chronic kidney disease, pre-diabetes, and obesity. Some of the company's nutraceutical products are Multibiotic, Mg Optima Relax, NRGBiotic, NanoCelle D3, SB 5B and others. The principal segments of the group are Nutraceutical which includes the sale of nutraceutical products; and Pharmaceutical research. It generates the majority of the revenue from the sale of nutraceutical products. The business operations of the firm are carried out from Australia.